Golden Throat Holdings Group Co Ltd (HK:6896)
:6896
Want to see HK:6896 full AI Analyst Report?
Top Page
Golden Throat Holdings Group Co Ltd
(6896)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$4.00
▲(30.29% Upside)
Action:DowngradedDate:04/29/26
The score is driven primarily by financial performance: strong margins are offset by 2025’s pronounced cash-flow deterioration and weaker revenue, plus higher leverage. Valuation is a major positive (low P/E and very high dividend yield), while technical signals are neutral-to-mixed and do not materially add conviction.
Positive Factors
High, stable margins
Sustained very high gross and healthy net margins indicate durable pricing power and tight cost control in a low-complexity consumer product. High margins support reinvestment, dividends and buffer profitability against modest volume swings over the next 2–6 months.
Negative Factors
Sharp 2025 cash-flow deterioration
A large year-over-year collapse in operating and free cash flow signals working-capital or execution stress that impairs the firm's ability to fund operations and discretionary spend. If persistent, it reduces financial flexibility and elevates refinancing or liquidity risk.
Read all positive and negative factors
Positive Factors
Negative Factors
High, stable margins
Sustained very high gross and healthy net margins indicate durable pricing power and tight cost control in a low-complexity consumer product. High margins support reinvestment, dividends and buffer profitability against modest volume swings over the next 2–6 months.
Read all positive factors
Golden Throat Holdings Group Co Ltd (6896) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.71B
Dividend Yield15.97%
Average Volume (3M)691.97K
Price to Earnings (P/E)8.3
Beta (1Y)0.19
Revenue Growth-20.14%
EPS Growth-20.91%
CountryHK
Employees874
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.25
Shares Outstanding739,302,000
10 Day Avg. Volume656,610
30 Day Avg. Volume691,973
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)1.47
Price to Sales (P/S)2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Golden Throat Holdings Group Co Ltd Business Overview & Revenue Model
Company Description
Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. It offers Golden Throat lozenges over-the-counter medicine t...
How the Company Makes Money
The company primarily makes money by selling branded throat lozenges and related throat-care products. Its core revenue stream is product sales, where earnings are driven by (1) unit volume sold through distribution into retail channels and (2) pr...
Golden Throat Holdings Group Co Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 979.71M | 918.85M | 1.19B | 961.38M | 992.01M | 820.54M |
| Gross Profit | 748.65M | 689.89M | 894.18M | 697.72M | 720.92M | 577.74M |
| EBITDA | 373.17M | 331.28M | 456.65M | 410.75M | 424.93M | 281.80M |
| Net Income | 268.11M | 244.70M | 318.63M | 250.16M | 281.22M | 187.64M |
Balance Sheet | ||||||
| Total Assets | 2.12B | 2.29B | 2.25B | 2.30B | 2.30B | 1.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.08B | 1.14B | 1.07B | 925.51M | 802.84M |
| Total Debt | 684.03M | 584.52M | 426.92M | 412.34M | 272.59M | 235.00M |
| Total Liabilities | 914.07M | 912.77M | 784.87M | 748.34M | 760.18M | 588.04M |
| Stockholders Equity | 1.21B | 1.38B | 1.47B | 1.55B | 1.54B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 185.70M | 77.99M | 408.65M | 221.30M | 255.30M | 116.23M |
| Operating Cash Flow | 238.09M | 123.31M | 475.87M | 238.84M | 271.15M | 164.89M |
| Investing Cash Flow | -12.19M | -55.02M | -41.60M | -59.67M | 36.59M | -145.11M |
| Financing Cash Flow | -87.37M | -228.90M | -335.18M | -79.38M | -142.01M | -10.21M |
Golden Throat Holdings Group Co Ltd Technical Analysis
Positive
3.07
Price Trends
3.37
Positive
3.29
Positive
3.59
Positive
Market Momentum
0.09
Positive
62.13
Neutral
60.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6896, the sentiment is Positive. The current price of 3.07 is below the 20-day moving average (MA) of 3.64, below the 50-day MA of 3.37, and below the 200-day MA of 3.59, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 62.13 is Neutral, neither overbought nor oversold. The STOCH value of 60.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6896.
Golden Throat Holdings Group Co Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$7.31B | 6.31 | 11.90% | 5.80% | -17.03% | 12.82% | |
75 Outperform | HK$1.98B | 5.29 | 20.10% | 9.98% | 12.83% | 36.12% | |
72 Outperform | HK$1.70B | 7.90 | 6.34% | 5.16% | 16.09% | -62.16% | |
68 Neutral | HK$2.71B | 8.28 | 19.22% | 15.97% | -20.14% | -20.91% | |
57 Neutral | HK$677.60M | 24.59 | 1.57% | 9.43% | -21.54% | -81.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$157.81M | -4.22 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:6896
Golden Throat Holdings Group Co Ltd
3.53
-0.35
-9.02%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.18
-37.50%
HK:2161
JBM (Healthcare) Ltd.
2.48
0.41
19.81%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.14
0.07
6.54%
HK:2877
China Shineway Pharmaceutical Group Limited
9.78
2.58
35.83%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.81
-0.05
-5.81%
Golden Throat Holdings Group Co Ltd Corporate Events
Golden Throat Updates Timetable for 2025 Final Dividend Payout
Apr 27, 2026
Golden Throat Holdings Group Company Limited has updated its previously announced final dividend for the year ended 31 December 2025, confirming a payout of HKD 0.34 per share, subject to shareholder approval at a meeting scheduled for 5 June 2026...
Golden Throat Profit Falls Over 20% in 2025 but Dividend Maintained
Mar 27, 2026
Golden Throat Holdings reported a sharp deterioration in 2025 results, with revenue falling 20.4% year on year to RMB943.3 million and gross profit down 19.8% to RMB717.0 million. Earnings before interest, taxes, depreciation and amortisation drop...
Golden Throat Declares HKD 0.34 Final Dividend for 2025
Mar 27, 2026
Golden Throat Holdings Group Company Limited has declared a final ordinary cash dividend of HKD 0.34 per share for the financial year ended 31 December 2025, payable in Hong Kong dollars. Shareholder approval, ex-dividend date, book closure period...
Golden Throat Sets March 2026 Board Meeting to Approve 2025 Results and Mull Dividend
Mar 17, 2026
Golden Throat Holdings Group Company Limited has scheduled a board meeting for 27 March 2026 to review and approve the annual results for the year ended 31 December 2025. The company, which is listed on the Hong Kong Stock Exchange and operates ou...
Golden Throat Issues Profit Warning on 20%–25% Earnings Decline for 2025
Mar 11, 2026
Golden Throat Holdings has warned that its operating revenue and profit for the year ended 31 December 2025 are expected to fall by 20%–25% from 2024 levels, based on a preliminary review of unaudited management accounts. The board attribute...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.